RecruitingNot applicableNCT06659458

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.

Checked against the public recordLast updated Mar 20, 2025 · Source: ClinicalTrials.gov

StatusRecruiting
PhaseNot applicable
U.S. locations1
SponsorOur Lady of the Lake Hospital
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Our Lady of the Lake Hospital
Interventions being studied
Other: blood draw; Other: Gene sequencing
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * 18-100 years old * Biologically born female * Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group) * No cancer diagnosis (Arm 2-health control) Exclusion Criteria: * less than 18 years of age * Biologically born male * Incarcerated at the time of participation

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Our Lady of the Lake Regional Medical CenterBaton Rouge, Louisiana

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 20, 2025. Always confirm current availability with the study team.

View original record ↗